Abstracts tagged "medication and pregnancy"

Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Min Kyung Chung ¹, Jin Su Park ², Hyun Sun Lim ², Chan Hee Lee ² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…
Abstract Number: 2112 • 2014 ACR/ARHP Annual Meeting
Patterns of Medication Use Before, During, and After Pregnancy Among Women with Systematic Lupus Erythematosus: A Population-Based Study
Mary De Vera¹, Eric C. Sayre², Corisande Baldwin³, Jessica Galo⁴ and J. Antonio Avina-Zubieta⁵, ¹University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years. Given the limited data on perinatal medication use among patients, our objective was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].